Cyclin B2 Antibody / CCNB2

Overview

In eukaryotic cells, mitosis is initiated following the activation of a protein kinase known variously as maturation-promoting factor, M phase specific histone kinase or M-phase kinase. This protein kinase is composed of a catalytic subunit (Cdc2), a regulatory subunit (cyclin B) and a low molecular weight subunit (p13-Suc1). The Cdc/cyclin enzyme is subject to multiple levels of control, of which the regulation of the catalytic subunit by tyrosine phosphorylation is the best understood. Tyrosine phosphorylation inhibits the Cdc2/ cyclin B enzyme, and tyrosine dephosphorylation, occurring at the onset of mitosis, directly activates the pre-MPF complex. Evidence has established that B type cyclins not only act on M phase regulatory subunits of the Cdc2 protein kinase, but also activate the Cdc25A and Cdc25B endogenous tyrosine phosphatase, of which Cdc2 is the physiological substrate. The two B type cyclins, cyclin B1 and cyclin B2, have been shown to have distinct tissue distributions.

This anti-CCNB2 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone X29.2, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: CCNB2
• Format: Purified
• Species reactivity: Human, Mouse, Rat
• Applications (listed): ELISA
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone X29.2, Mouse IgG1, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

CCNB2 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling CCNB2 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link CCNB2 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• ELISA

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.